These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

214 related articles for article (PubMed ID: 23725475)

  • 1. A common polymorphic allele of the LH beta-subunit gene is associated with higher exogenous FSH consumption during controlled ovarian stimulation for assisted reproductive technology.
    Alviggi C; Pettersson K; Longobardi S; Andersen CY; Conforti A; De Rosa P; Clarizia R; Strina I; Mollo A; De Placido G; Humaidan P
    Reprod Biol Endocrinol; 2013 Jun; 11():51. PubMed ID: 23725475
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Recombinant follicle-stimulating hormone and recombinant luteinizing hormone versus recombinant follicle-stimulating hormone alone during GnRH antagonist ovarian stimulation in patients aged ≥35 years: a randomized controlled trial.
    Vuong TN; Phung HT; Ho MT
    Hum Reprod; 2015 May; 30(5):1188-95. PubMed ID: 25740882
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Effect of domestic highly purified urinary follicle stimulating hormone on outcomes of in vitro fertilization-embryo transfer in controlled ovarian stimulation].
    Ye H; Huang GN; Cao YX; Zhong Y; Huang YH; Zhu GJ; Zhou LM; Chen ZJ; Shi JZ; Zeng Y; Weng N; Huang XF; Yang J; Zhu YM; Li YP; Yi D; Zhuang GL
    Zhonghua Fu Chan Ke Za Zhi; 2013 Nov; 48(11):838-42. PubMed ID: 24444561
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism.
    Alviggi C; Clarizia R; Pettersson K; Mollo A; Humaidan P; Strina I; Coppola M; Ranieri A; D'Uva M; De Placido G
    Reprod Biomed Online; 2009 Jan; 18(1):9-14. PubMed ID: 19146763
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and safety of follitropin alfa/lutropin alfa in ART: a randomized controlled trial in poor ovarian responders.
    Humaidan P; Chin W; Rogoff D; D'Hooghe T; Longobardi S; Hubbard J; Schertz J;
    Hum Reprod; 2017 Mar; 32(3):544-555. PubMed ID: 28137754
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of recombinant LH supplementation to recombinant FSH during induced ovarian stimulation in the GnRH-agonist protocol: a matched case-control study.
    Franco JG; Baruffi RL; Oliveira JB; Mauri AL; Petersen CG; Contart P; Felipe V
    Reprod Biol Endocrinol; 2009 Jun; 7():58. PubMed ID: 19497101
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Effects of recombinant LH supplementation in women undergoing assisted reproduction with GnRH agonist down-regulation and stimulation with recombinant FSH: an opening study.
    Humaidan P; Bungum M; Bungum L; Yding Andersen C
    Reprod Biomed Online; 2004 Jun; 8(6):635-43. PubMed ID: 15169576
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The evaluation of recombinant LH supplementation in patients with suboptimal response to recombinant FSH undergoing IVF treatment with GnRH agonist down-regulation.
    Yazıcı Yılmaz F; Görkemli H; Çolakoğlu MC; Aktan M; Gezginç K
    Gynecol Endocrinol; 2015 Feb; 31(2):141-4. PubMed ID: 25237892
    [TBL] [Abstract][Full Text] [Related]  

  • 9. FSHB -211 G>T is a major genetic modulator of reproductive physiology and health in childbearing age women.
    Rull K; Grigorova M; Ehrenberg A; Vaas P; Sekavin A; Nõmmemees D; Adler M; Hanson E; Juhanson P; Laan M
    Hum Reprod; 2018 May; 33(5):954-966. PubMed ID: 29617818
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Recombinant LH supplementation to a standard GnRH antagonist protocol in women of 35 years or older undergoing IVF/ICSI: a randomized controlled multicentre study.
    König TE; van der Houwen LE; Overbeek A; Hendriks ML; Beutler-Beemsterboer SN; Kuchenbecker WK; Renckens CN; Bernardus RE; Schats R; Homburg R; Hompes PG; Lambalk CB
    Hum Reprod; 2013 Oct; 28(10):2804-12. PubMed ID: 23838159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A randomized comparison of two ovarian stimulation protocols with gonadotropin-releasing hormone (GnRH) antagonist cotreatment for in vitro fertilization commencing recombinant follicle-stimulating hormone on cycle day 2 or 5 with the standard long GnRH agonist protocol.
    Hohmann FP; Macklon NS; Fauser BC
    J Clin Endocrinol Metab; 2003 Jan; 88(1):166-73. PubMed ID: 12519847
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ratio of exogenous Luteinizing hormone to Follicle stimulating hormone administered for controlled ovarian stimulation is associated with oocytes' number and competence.
    Albu D; Albu A
    Biosci Rep; 2020 Jan; 40(1):. PubMed ID: 31850491
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of human menopausal gonadotrophin and highly purified, urine-derived follicle stimulating hormone on the outcome of in-vitro fertilization in down-regulated normogonadotrophic women.
    Westergaard LG; Erb K; Laursen S; Rasmussen PE; Rex S
    Hum Reprod; 1996 Jun; 11(6):1209-13. PubMed ID: 8671425
    [TBL] [Abstract][Full Text] [Related]  

  • 14. LH serum levels during ovarian stimulation as predictors of ovarian response and assisted reproduction outcome in down-regulated women stimulated with recombinant FSH.
    Peñarrubia J; Fábregues F; Creus M; Manau D; Casamitjana R; Guimerá M; Carmona F; Vanrell JA; Balasch J
    Hum Reprod; 2003 Dec; 18(12):2689-97. PubMed ID: 14645193
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The serum follicle stimulating hormone-to-luteinizing hormone ratios can predict assisted reproductive technology outcomes in women undergoing gonadotropin releasing hormone antagonist protocol.
    Zhao S; Xu H; Wu X; Xia L; Li J; Zhang D; Zhang A; Xu B
    Front Endocrinol (Lausanne); 2023; 14():1093954. PubMed ID: 36793280
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recombinant human LH supplementation versus recombinant human FSH (rFSH) step-up protocol during controlled ovarian stimulation in normogonadotrophic women with initial inadequate ovarian response to rFSH. A multicentre, prospective, randomized controlled trial.
    De Placido G; Alviggi C; Perino A; Strina I; Lisi F; Fasolino A; De Palo R; Ranieri A; Colacurci N; Mollo A;
    Hum Reprod; 2005 Feb; 20(2):390-6. PubMed ID: 15576390
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Role of Lh polymorphisms and r-hLh supplementation in GnRh agonist treated ART cycles: A cross sectional study.
    G A R; Cheemakurthi R; Prathigudupu K; Balabomma KL; Kalagara M; Thota S; Kota M
    Eur J Obstet Gynecol Reprod Biol; 2018 Mar; 222():119-125. PubMed ID: 29408742
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Variant-beta luteinizing hormone is not associated with poor ovarian response to controlled ovarian hyperstimulation.
    Hanevik HI; Hilmarsen HT; Skjelbred CF; Tanbo T; Kahn JA
    Reprod Biol Endocrinol; 2014 Mar; 12():20. PubMed ID: 24625195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suboptimal response to GnRHa long protocol is associated with a common LH polymorphism.
    Alviggi C; Clarizia R; Pettersson K; Mollo A; Humaidan P; Strina I; Coppola M; Ranieri A; D'Uva M; De Placido G
    Reprod Biomed Online; 2011 Feb; 22 Suppl 1():S67-72. PubMed ID: 21575852
    [TBL] [Abstract][Full Text] [Related]  

  • 20. IVF/ICSI outcomes between cycles with luteal estradiol (E2) pre-treatment before GnRH antagonist protocol and standard long GnRH agonist protocol: a prospective and randomized study.
    Ye H; Huang GN; Zeng PH; Pei L
    J Assist Reprod Genet; 2009 Mar; 26(2-3):105-11. PubMed ID: 19225876
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.